Intranasal corticosteroids: The development of a drug delivery device for fluticasone furoate as a potential step toward improved compliance

Expert Opinion on Drug Delivery

Volumn 4, Issue 6, 2007, Pages 689-701

  Berger, William E ^a   Godfrey, James W ^b   Slater, Anna L ^b  

^a Allergy & Asthma Associates of Northern California   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Allergic rhinitis; Ergonomic design; Fine mist; Intranasal corticosteroids; Nasal drug delivery; Sensory attributes; Short delivery nozzle; Side actuated mechanism

Indexed keywords

ANTIHISTAMINIC AGENT; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DECONGESTIVE AGENT; FLUTICASONE FUROATE; FLUTICASONE PROPIONATE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MOMETASONE FUROATE; TRIAMCINOLONE ACETONIDE;

ALLERGIC RHINITIS; ARTICLE; BINDING AFFINITY; BIOMEDICAL TECHNOLOGY ASSESSMENT; BURNING SENSATION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DISEASE SEVERITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRY NOSE; DRY POWDER; DRY THROAT; EPISTAXIS; EQUIPMENT DESIGN; ERGONOMICS; FIRST PASS EFFECT; HAY FEVER; HEALTH CARE NEED; HUMAN; HUMAN FACTORS RESEARCH; LIVER METABOLISM; LOW DRUG DOSE; METERED DOSE INHALER; MUCOSA INFLAMMATION; NOSE MUCOSA; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; PERENNIAL RHINITIS; QUALITATIVE ANALYSIS; SIDE EFFECT; SOCIOECONOMICS; TASTE AVERSION;

ADMINISTRATION, INTRANASAL; ADRENAL CORTEX HORMONES; ANDROSTADIENES; ANTI-ALLERGIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; PATIENT COMPLIANCE; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL;

EID: 36648999352     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.4.6.689     Document Type: Article

References (54)

1. CIPRANDI G, PASSALACQUA G: Emerging anti-inflammatory agents for allergic rhinitis. Expert Opin. Emerging Drugs (2005) 10:689-705.
2. BOUSQUET J, VAN CAUWENBERGE P, KHALTAEV N: Allergic rhinitis and its impact on asthma. J. Allergy Clin. Immunol. (2001) 108:S147-S334.
3. GANDHI RK, BLAISS MS: Current concepts and therapeutic strategies for allergic rhinitis. Otorinolaringologia (2005) 55:187-201.
4. MELTZER EO: Quality of life in adults and children with allergic rhinitis. J. Allergy Clin. Immunol. (2001) 108:S45-S53.
5. LEYNAERT B, NEUKIRCH F, DEMOLY P, BOUSQUET J: Epidemiologic evidence for asthma and rhinitis comorbidity. J. Allergy Clin. Immunol. (2000) 106:S201-S205.
6. REED SD, LEE TA, MCCRORY DC: The economic burden of allergic rhinitis: a critical evaluation of the literature. Pharmacoeconomics (2004) 22:345-361.
7. BAROODY FM: Allergic rhinitis: broader disease effects and implications for management. Otolaringol. Head Neck Surg. (2003) 128:616-631.
8. TASK FORCE ON ALLERGIC DISORDERS: The Allergy Report. Milwaukee, WI: American Academy of Allergy. Asthma Immunology (2000).
9. BAUCHAU V, DURHAM SR: Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur. Respir. J. (2004) 24:758-764.
10. VAN DRUNEN C, MELTZER EO, BACHERT C et al.: Nasal allergies and beyond: a clinical review of the pharmacology, efficacy and safety of mometasone furoate. Allergy (2005) 60(Suppl. 80):5-19.
11. DYKEWICZ MS, FINEMAN S, SKONER DP et al.: Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann. Allergy Asthma Immunol. (1998) 81:478-518.
12. INTERNATIONAL RHINITIS MANAGEMENT WORKING GROUP: International consensus report on the diagnosis and management of rhinitis. Allergy (1994) 49:1-34.
13. VAN CAUWENBERGE P, BACHERT C, PASSALACQUA G et al.: Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy (2000) 55:116-134.
14. BERGER WE: Long-term combination therapy is often necessary - getting allergic rhinitis under control: Part II. J. Respir. Dis. (2005) 26:188-194.
15. BERNSTEIN DI, LEVY AL, HAMPEL FC et al.: Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. Clin. Exp. Allergy (2004) 34:952-957.
16. WADDELL AN, PATEL SK, TOMA AG, MAW AR: Intranasal steroid sprays in the treatment of rhinitis: is one better than another? J. Laryngol. Otol. (2003) 117:843-845.
17. ROSENBLUT A, BARDIN PG, MULLER B et al.: Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis. Allergy (2007) 62:1071-1077.
18. KOEPKE JW, BEAUCHER WN, KOBAYASHI RH et al.: Long-term safety and efficacy of triamcinolone acetonide aqueous nasal spray for the treatment of perennial allergic rhinitis. Allergy Asthma Proc. (1997) 18:33-37.
19. BACHERT C, LUKAT KF, LANGE B: Effect of intranasal fluticasone propionate and triamcinolone acetonide on basal and dynamic measures of hypothalamic-pituitary-adrenal-axis activity in healthy volunteers. Clin. Exp. Allergy (2004) 34:85-90.
20. BRANNAN MD, HERRON JM, AFFRIME MB: Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin. Ther. (1997) 19: 1330-1339.
21. GALANT SP, MELAMED IR, NAYAK AS et al.: Lack of effect of fluticasone propionate aqueous nasal spray on the hypothalamic-pituitary-adrenal axis in 2- and 3-year-old patients. Pediatrics (2003) 112:96-100.
22. TRANGSRUD AJ, WHITAKER AL, SMALL RE: Intranasal corticosteroids for allergic rhinitis. Pharmacotherapy (2002) 22:1458-1467.
23. WALLS RS, HEDDLE RJ, TANG ML et al.: Optimising the management of allergic rhinitis: an Australian perspective. Med. J. Aust. (2005) 182:28-33.
24. BOUSQUET J, VAN CAUWENBERGE P, BACHERT C et al.: Requirements for medications commonly used in the treatment of allergic rhinitis. European Academy of Allergy and Clinical Immunology (EAACI), Allergic Rhinitis and its Impact on Asthma (ARIA). Allergy (2003) 58:192-197.
25. SOUTHALL J, ELLIS C: Developments in nasal drug delivery. Innov. Pharmaceut. Technol. (2000):110-115.
26. DJUPESLAND PG, SKREITING A, WINDEREN M, HOLAND T: Breath actuated device improves delivery to target sites beyond the nasal valve. Laryngoscope (2006) 116:466-472.
27. SHECKLER MT, THEODORAKIS A: Bespak nasal drug delivery devices. Milton Keynes, UK: Bespak nasal drug delivery focus group - Quarterly Newsletter (2002).
28. AGARWAL V, MISHRA B: Recent trends in drug delivery systems: intranasal drug delivery. Indian J. Exp. Biol. (1999) 37:6-16.
29. KHANNA P, SHAH A: Assessment of sensory perceptions and patient preference for intranasal corticosteroid sprays in allergic rhinitis. Am. J. Rhinol. (2005) 19:316-321.
30. MAHADEVIA PJ, SHAH S, LEIBMAN C et al.: Patient preferences for sensory attributes of intranasal corticosteroids and willingness to adhere to prescribed therapy for allergic rhinitis: a conjoint analysis. Ann. Allergy Asthma Immunol. (2004) 93:345-350.
31. MELTZER EO, BARDELAS J, GOLDSOBEL A, KAISER H: A preference evaluation study comparing the sensory attributes of mometasone furoate and fluticasone propionate nasal sprays by patients with allergic rhinitis. Treat. Respir. Med. (2005) 4:289-296.
32. STOKES M, AMOROSI SL, THOMPSON D et al.: Evaluation of patients' preferences for triamcinolone acetonide aqueous, fluticasone propionate, and mometasone furoate nasal sprays in patients with allergic rhinitis. Otolaryngol Head Neck Surg. (2004) 131:225-231.
33. KUBLIK H, VIDGREN MT: Nasal delivery systems and their effect on deposition and absorption. Adv. Drug Deliv. Rev. (1998) 29:157-177.
34. PATEL RS, MCGARRY GW: Most patients overdose on topical nasal corticosteroid drops: an accurate delivery device is required. J. Laryngol. Otol. (2001) 115:633-635.
35. AGGARWAL R, CARDOZO A, HOMER JJ: The assessment of topical nasal drug distribution. Clin. Otolaryngol. Allied Sci. (2004) 29:201-205.
36. BACHERT C, EL AKKAD T: Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis. Ann. Allergy Asthma Immunol. (2002) 89:292-297.
37. MARTINI A, MUGGETTI L, WARCHOL MP: Nasal and pulmonary drug delivery systems. Expert Opin. Ther. Patent (2000) 10:315-323.
38. ASTRAZENECA: Rhinocort product leaflet. Macclesfield, UK: AstraZeneca (2005).
39. GLAXOSMITHKLINE: Flonase product leaflet. Brentford, UK: GlaxoSmithKline (2005).
40. SCHERING-PLOUGH: Nasonex product leaflet. Kenilworth, NJ: Schering-Plough (2005).
41. BENNINGER MS, HADLEY JA, OSGUTHORPE JD et al.: Techniques of intranasal steroid use. Otolaryngol. Head Neck Surg. (2004) 130:5-24.
42. SALTER M, BIGGADIKE K, MATTHEWS JL et al.: Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am. J. Physiol. Lung Cell Mol. Physiol. (2007) 293:L660-L667.
43. ALLEN A, DOWN D, NEWLANDS A et al.: Tolerability, safety, pharmacokinetics and bioavailability of the new cortocosteroid aqueous nasal spray fluticasone furoate in healthy subjects. Presented at the American College of Allergy, Asthma & Immunology Annual Meeting, Philadelphia, PA, (9-15 November 2006).
44. ALLEN A, DOWN G, NEWLAND A et al.: Absolute bioavailability of intranasal fluticasone furoate in healthy subjects. Clin. Ther. (2007) 29:1415-1420.
45. STUEBNER P: Effects of the novel intranasal glucocorticosteroid GW685698 (200 μg once-daily) on seasonal allergic rhinitis (SAR) symptoms induced in the Vienna Challenge Chamber model (VCC). J. Allergy Clin. Immunol. (2006) 117(2 Suppl. S):S319.
46. NEWMAN SP, MOREN F, CLARKE SW: Deposition pattern of nasal sprays in man. Rhinology (1987) 26:111-120.
47. KAISER HB, NACLERIO R, GIVEN J et al.: Once-daily fluticasone furoate nasal spray (FFNS) is effective for the treatment of seasonal allergic rhinitis (SAR) caused by ragweed. J. Allergy Clin. Immunol. (2007) 119(1 Suppl.):S232.
48. FOKKENS WJ, JOGI R, REINARTZ S et al.: Once daily fluticasone furoate nasal spray is effective in seasonal allergic rhinitis caused by grass pollen. Allergy (2007) 62:1078-1084.
49. HALLWORTH GW, PADFIELD JM: A comparison of the regional deposition in a model nose of a drug discharged from metered aerosol and metered-pump nasal delivery systems. J. Allergy Clin. Immunol. (1986) 77:348-353.
50. SLATER A, ELDER D, FISHER C et al.: A quality by design approach for the development of a next generation nasal spray delivery system. XXVI Congress of the European Academy of Allergology and Clinical Immunology. Göteborg, Sweden (9 - 13 June 2007).
51. EMEA: Guideline on the pharmaceutical quality of inhalation and nasal products. London, UK: European Medicines Agency (2006).
52. FDA: Guidance for industry: Nasal spray and inhalation solution, suspension, and spray drug products - chemistry, manufacturing, and controls documentation. Rockville, MD: US Department of Health & Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (2002).
53. HEALTH CANADA: Guidance for industry: pharmaceutical quality of inhalation and nasal products. Ottawa, ON: Health Canada (2006).
54. GODFREY JW, GRANT AC, SLATER AL: Fluticasone furoate (FF) nasal spray - ergonomic considerations for a next generation delivery system. J. Allergy Clin. Immunol. (2007) 119:S230.